Pepcid AC and PPIs
This article was originally published in The Tan Sheet
Executive Summary
Study showing effectiveness of J&J/Merck's famotidine H2 antagonist brings end to NAD challenge by Pfizer/Warner-Lambert, CBBB division says in November Case Reports. Zantac 75 and Rolaids marketer objected to three ads calling Pepcid a "complement" to Rx proton pump inhibitors such as AstraZeneca's Prilosec. While noting firm should have substantiated claims before making them, NAD closes case